Ancora Pharmaceuticals Inc. is proud to welcome Dr. Florian Schodel to its team of scientific advisors. Dr. Schodel, formerly of Merck Research Labs, is considered a leading authority in biologics and vaccine development. He will bring a wealth of knowledge to Ancora as it moves its vaccine candidates to the clinic.
"Dr. Schodel has extensive pre-clinical and clinical development experience within the vaccine field," said Dr. John Pena, Ancora's president. "As Ancora is entering pre-clinical development with its unique, synthetic carbohydrate-based vaccines, we are confident Dr. Schodel will contribute invaluable program insight."
Dr. Schodel joined Merck in 1996 and most recently held the position of vice president of Infectious Diseases and Vaccine Clinical Research where he led clinical vaccine development for both new and legacy vaccine products. During his tenure at Merck, Dr. Schodel spearheaded and oversaw the clinical development of many of the company's commercial vaccines, including RotaTeq(R), ZOSTAVAX(R) and ProQuad(R).
"Ancora's synthetic approach to producing complex carbohydrates has the potential to lead to new and better defined glycoconjugate vaccines," said Schodel. "I am delighted to be an advisor to Ancora as its emerging pipeline moves forward toward clinical development."Ancora Pharmaceuticals is a private biopharmaceutical company based in Medford, Massachusetts. Using its patented, world-leading carbohydrate synthesis technology, Ancora is developing several promising synthetic carbohydrate-based vaccines. Ancora's carbohydrate synthesis platform enables the rapid production of synthetic carbohydrates to support vaccine discovery and optimization, clinical trials and product commercialization.
No comments:
Post a Comment